YO-2
YO-2 is a plasmin inhibitor and TP53 upregulator with anti-tumor and apoptosis-inducing activities. YO-2 upregulates the expression of TP53 and the tumor-suppressive miR-103/107, downregulates LRP1, and induces cellular DNA fragmentation and caspase cascade activation. YO-2 effectively blocks the growth of melanoma. YO-2 has been widely used in studies related to melanoma and colon cancer.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 288254-44-4
- Fòrmula: C31H46N4O3
- Peso molecular:522.72
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
YO-2 (10-30 μM; 24 h) dose-dependently inhibits plasminogen-induced proliferation of murine B16F10 melanoma cells after 24 h of incubation[1].
YO-2 (10-30 μM; 24 h) dose-dependently activates caspase 3/7 in murine B16F10 melanoma cells, with a ~10-fold increase in activity at 30 μM after 24 h of incubation[1].
YO-2 (10-30 μM; 24 h) dose-dependently downregulates anti-apoptotic BCL2 gene expression in murine B16F10 melanoma cells after 24 h of incubation[1].
YO-2 (10-20 μM) increases p53 protein levels in murine B16F10 melanoma cells at concentrations of 10 μM and 20 μM[1].
YO-2 (10-30 μM) dose-dependently upregulates p53 protein levels in murine B16F10 melanoma cells at concentrations of 10 μM, 20 μM, and 30 μM[1].
YO-2 (30 μM; 1-6 h) induces apoptotic morphological changes in rat thymocytes, including time-dependent phosphatidylserine translocation and chromatin condensation, when treated with 30 μM YO-2 for 1 to 6 h[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:murine B16F10 melanoma cells
-
Concentration:10-30 μM
-
Incubation Time:24 h
-
Result:Increased caspase 3/7 activity in a dose-dependent fashion.
Induced a ~3-fold increase at 10 μM compared to PBS-treated controls.
Induced a ~6-fold increase at 20 μM compared to PBS-treated controls.
Induced a ~10-fold increase at 30 μM compared to PBS-treated controls.
Cotreatment with YO-2 (5 mg/kg; i.p.; every other day; starting day 5 post-tumor inoculation) and a single 1 mg/kg dose of Doxorubicin (HY-15142A) (day 0 post-tumor inoculation) significantly reduces melanoma tumor weight more effectively than either agent alone in a murine subcutaneous melanoma model[1].
YO-2 (5 mg/kg; i.p.; daily; starting day 5 post-tumor inoculation) significantly reduces tumor weight in mice bearing LRP1-overexpressing subcutaneous melanoma tumors[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (8- to 12-week-old male; wild-type; subcutaneous inoculation of 1×106 B16F10 melanoma cells)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; daily; starting day 5 post-tumor inoculation
-
Result:Reduced mean tumor weight from ~3.2 g (control) to ~1.0 g.
Increased expression of TP53, p21, miR-103, and miR-107 in tumor tissues.
Decreased expression of LRP1 in tumor tissues.
-
Animal Model:C57BL/6 (8- to 12-week-old male; wild-type; subcutaneous inoculation of 1×106 B16F10 melanoma cells)[1]
-
Dosage:5 mg/kg (YO-2); 1 mg/kg (doxorubicin)
-
Administration:i.p. (YO-2; every other day; starting day 5 post-tumor inoculation); single dose (doxorubicin; day 0 post-tumor inoculation)
-
Result:Reduced mean tumor weight to ~0.7 g, compared to ~2.8 g (untreated control), ~1.5 g (YO-2 alone), and ~2.5 g (doxorubicin alone).
-
Animal Model:C57BL/6 (8- to 12-week-old male; wild-type; subcutaneous inoculation of 1×106 LRP1-overexpressing B16F10 melanoma cells)[1]
-
Dosage:5 mg/kg
-
Administration:i.p.; daily; starting day 5 post-tumor inoculation
-
Result:Reduced mean tumor weight from ~4.0 g (untreated control) to ~2.0 g in LRP1-overexpressing tumors.
Chemical Information
-
No. CAS 288254-44-4
-
Peso molecular 522.72
-
Fòrmula C31H46N4O3
-
SMILES
O=C([C@H]1CC[C@@H](CC1)CN)N[C@H](C(NCCCCCCCC)=O)CC2=CC=C(C=C2)OCC3=CC=NC=C3
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Salama Y, et al. YO2 Induces Melanoma Cell Apoptosis through p53-Mediated LRP1 Downregulation. Cancers (Basel). 2022;15(1):288. Published 2022 Dec 31. [Content Brief]
[2]. Lee E, et al. A selective plasmin inhibitor, trans-aminomethylcyclohexanecarbonyl-L-(O-picolyl)tyrosine-octylamide (YO-2), induces thymocyte apoptosis. Biochem Pharmacol. 2002;63(7):1315-1323. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
YO-2 Related Classifications
HY-183877 Related Classifications
Powered by Bioz